The device was recalled last February due to dosing accuracy concerns. While Paris-based Sanofi had licensed and manufactured Auvi-Q, the company returned the rights to Kaleo after the recall, according to the report.
Once back on the market, Auvi-Q will compete with Mylan’s EpiPen, which has a list price of $608 for a pack of two.
Kaleo declined to comment on a list price for Auvi-Q, but CEO Spencer Williamson told Reuters: “We are working on what is the right price to assure that the ultimate patient co-pay is low.”
While Auvi-Q delivers the same epinephrine as EpiPen, the device is shaped like a credit card and contains a voice system to prompt users administering the device.
Mr. Williamson said the devices will be manufactured at an automated robotic production line in the Midwest.
More articles on supply chain:
HSCA’s ‘Total Visibility Project’ boosts available product info for GPOs, providers
FDA approved Merck’s Keytruda as first line treatment against lung cancer
Supply chain tip of the week: Use evidence-based collaboration to drive clinician engagement
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
